

10 December 2015

Lipa CEO Appointed as CMA President

Complementary Medicines Australia (CMA) has welcomed the election of Dusko Pejnovic, Chief Executive Officer of Lipa Pharmaceuticals, to the presidency of the CMA Board.

“We are delighted to welcome Dusko into his role as President of CMA. Dusko’s knowledge of the industry is invaluable, as is his vision for the development of the complementary medicines sector and its recognition as a vital component of the Australian healthcare landscape,” said Mr Carl Gibson, Chief Executive Officer of CMA.

“Dusko has been an active member on the CMA Board since 2008 and, with a background that incorporates senior executive roles across pharmaceuticals, foods, FMCG and services, brings a broad range of commercial experience to the table,” said Mr Gibson.

CMA is also pleased to announce that past President, Mr Richard Henfrey from Blackmores, has been appointed to the role of Vice President.

“We thank Richard for his valuable contribution to the industry during his tenure as President and are delighted that he will remain an active member of the Board.”

“CMA is excited about taking the industry forward, continuing in our work to ensure that consumers have access to an ongoing stream of locally manufactured, innovative and high quality products,” said Mr Gibson.

More information about Complementary Medicines Australia and members of the Board can be found on the CMA website: www.cmaustralia.org.au

ENDS

Dusko Pejnovic CEO, Lipa Pharmaceuticals

Dusko has over thirty years of broad based commercial experience in senior executive roles that encompass business development, sales and marketing, production, technical services and quality functions. This experience base is complemented with formal tertiary training in business, chemistry and engineering.



For Media Interviews or Further Information Contact:

CMA, Chief Executive

Carl Gibson

+61 457 028 974